[go: up one dir, main page]

PE20090895A1 - Derivados de triazol como inhibidores de la jak quinasa - Google Patents

Derivados de triazol como inhibidores de la jak quinasa

Info

Publication number
PE20090895A1
PE20090895A1 PE2008001287A PE2008001287A PE20090895A1 PE 20090895 A1 PE20090895 A1 PE 20090895A1 PE 2008001287 A PE2008001287 A PE 2008001287A PE 2008001287 A PE2008001287 A PE 2008001287A PE 20090895 A1 PE20090895 A1 PE 20090895A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrazole
alkenyl
methyl
jak
Prior art date
Application number
PE2008001287A
Other languages
English (en)
Spanish (es)
Inventor
Lynsie Almeida
Brian Aquila
Claudio Edmundo Chuaqui
Huiping Guan
Shan Huang
Stephanos Ioannidis
Michelle Lamb
Bo Peng
Jie Shi
Mei Su
Quibin Su
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090895(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090895A1 publication Critical patent/PE20090895A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2008001287A 2007-07-31 2008-07-31 Derivados de triazol como inhibidores de la jak quinasa PE20090895A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95315807P 2007-07-31 2007-07-31

Publications (1)

Publication Number Publication Date
PE20090895A1 true PE20090895A1 (es) 2009-08-08

Family

ID=40304964

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001287A PE20090895A1 (es) 2007-07-31 2008-07-31 Derivados de triazol como inhibidores de la jak quinasa

Country Status (6)

Country Link
AR (1) AR069899A1 (fr)
CL (1) CL2008002243A1 (fr)
PE (1) PE20090895A1 (fr)
TW (1) TW200906818A (fr)
UY (1) UY31254A1 (fr)
WO (1) WO2009016410A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
WO2010144338A1 (fr) * 2009-06-08 2010-12-16 Abraxis Bioscience, Llc Dérivés de triazine et leurs applications thérapeutiques
CA2765044A1 (fr) * 2009-06-09 2010-12-16 California Capital Equity, Llc Derives de la triazine substituee au benzyle et leurs applications therapeutiques
AR077292A1 (es) 2009-06-29 2011-08-17 Agios Pharmaceuticals Inc Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas
ES2594402T3 (es) 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Métodos y composiciones para trastornos relacionados con la proliferación celular
HUE065700T2 (hu) 2011-05-03 2024-06-28 Agios Pharmaceuticals Inc Piruvát-kináz aktivátorok terápiában történõ alkalmazásra
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AR091858A1 (es) * 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
JP6385352B2 (ja) 2012-10-15 2018-09-05 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
WO2015003355A2 (fr) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
AU2014287121B2 (en) 2013-07-11 2018-11-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
CN105517996B (zh) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA2942072C (fr) 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Compositions pharmaceutiques et utilisation de (s)-1-(2-chlorophenyle)-2-((3,3-di fluorocyclobutyle)amino)-2-oxoethyle)-1-(4-cyanopyridin-2-yl)-n-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
WO2016113277A1 (fr) 2015-01-16 2016-07-21 Bayer Cropscience Aktiengesellschaft Procédé de préparation de chlorhydrate de 4-cyanopipéridine
PL3307271T3 (pl) 2015-06-11 2024-02-05 Agios Pharmaceuticals, Inc. Sposoby stosowania aktywatorów kinazy pirogronianowej
IL258684B2 (en) 2015-10-15 2023-04-01 Agios Pharmaceuticals Inc Combination therapy including an isocitrate dehydrogenase (1idh) inhibitor for use in the treatment of acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of 1idh
RS62829B1 (sr) 2015-10-15 2022-02-28 Servier Lab Kombinovana terapija za lečenje maligniteta
WO2019046316A1 (fr) * 2017-08-28 2019-03-07 Acurastem Inc. Inhibiteurs de kinases pikfyve
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2019245910A1 (fr) * 2018-06-22 2019-12-26 Aduro Biotech, Inc. Composés de triazine et leurs utilisations
CN109020951B (zh) * 2018-08-24 2020-06-02 大连理工大学 含三取代三聚氯氰的萘酰亚胺类衍生物及其合成方法和应用
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CA3167339A1 (fr) 2020-01-13 2021-07-22 Verge Analytics, Inc. Pyrazolo-pyrimidines substituees et leurs utilisations
IL297437A (en) 2020-05-13 2022-12-01 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638926B2 (en) * 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2432799C (fr) * 2000-12-21 2008-08-19 Vertex Pharmaceuticals Incorporated Composes de pyrazole presentant une grande utilite comme inhibiteurs de proteine kinase
AU2003225800A1 (en) * 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
EP1899323A2 (fr) * 2005-05-16 2008-03-19 AstraZeneca AB Dérivés de pyrazolylaminopyrimidine utiles comme inhibiteurs de tyrosine kinase
EP2388259A1 (fr) * 2005-10-28 2011-11-23 AstraZeneca AB Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu'inhibiteurs de tyrosine kinases dans le cadre d'un traitement anticancereux

Also Published As

Publication number Publication date
TW200906818A (en) 2009-02-16
CL2008002243A1 (es) 2009-08-21
UY31254A1 (es) 2009-04-30
WO2009016410A3 (fr) 2009-07-02
AR069899A1 (es) 2010-03-03
WO2009016410A2 (fr) 2009-02-05

Similar Documents

Publication Publication Date Title
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20141681A1 (es) Inhibidores de btk
PE20140934A1 (es) Derivados de pirazol
PE20150621A1 (es) Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20131377A1 (es) Triazina-oxadiazoles
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20050681A1 (es) PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
PE20090887A1 (es) DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6
NZ591449A (en) Picolinamide derivatives as kinase inhibitors
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
PE20100087A1 (es) Compuestos y composiciones como inhibidores de cinasa
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20160691A1 (es) Nuevos derivados de triazolo[4,5-d]pirimidina

Legal Events

Date Code Title Description
FD Application declared void or lapsed